Abstract
Antiviral Therapeutics: Pipelines and Competitive Dynamics assesses the
compounds, the clinical data, the companies, and the market-shifting
developments in the antiviral therapeutic category. Sales of antiviral agents
currently constitute 25% of the anti-infective drug market. The ability of
viruses to develop resistance against drugs, coupled with sub-optimal
treatment outcomes as a result of failure of patients to comply with the full
course of therapy, will continue to provide the commercial and medical
incentive for intense R&D activity.
Until recently, much of the effort to develop new antiviral agents was
directed toward improved agents for the treatment of HIV and Hepatitis C
(HCV). While these indications continue to attract research dollars and to
make measurable progress with respect to dosing, deliverability, and efficacy,
several new developments have reignited interest in antiviral disease R&D.
These include concern about the evolution of avian influenza into a lethal
pandemic and recent approvals for vaccines against certain strains of Human
Papilloma Virus (HPV) that are associated with high rates of cervical cancer.
Antiviral Therapeutics: Pipelines and Competitive Dynamics surveys the
5 major viral disease categories and their sub-indications- HIV, Hepatitis,
Herpes Viruses, Human Papilloma Viruses, and Respiratory Viruses.
For each indication, the report provides:
- Pathophysiology, incidence and prevalence, symptoms and sequelae.
- Assessment of current treatment options.
- Assessment of unmet medical need.
- Assessment of compounds in development (by agent and by mechanism of
action).
- Profiles of companies active in antiviral R&D
| 
View Cart
